130 related articles for article (PubMed ID: 17188754)
1. Interferon receptor expression in multiple sclerosis patients.
Oliver B; Mayorga C; Fernández V; Leyva L; León A; Luque G; López JC; Tamayo JA; Pinto-Medel MJ; de Ramon E; Blanco E; Alonso A; Fernández O
J Neuroimmunol; 2007 Feb; 183(1-2):225-31. PubMed ID: 17188754
[TBL] [Abstract][Full Text] [Related]
2. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response.
Leyva L; Fernández O; Fedetz M; Blanco E; Fernández VE; Oliver B; León A; Pinto-Medel MJ; Mayorga C; Guerrero M; Luque G; Alcina A; Matesanz F
J Neuroimmunol; 2005 Jun; 163(1-2):165-71. PubMed ID: 15885318
[TBL] [Abstract][Full Text] [Related]
3. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.
Gilli F; Valentino P; Caldano M; Granieri L; Capobianco M; Malucchi S; Sala A; Marnetto F; Bertolotto A
Neurology; 2008 Dec; 71(24):1940-7. PubMed ID: 18971450
[TBL] [Abstract][Full Text] [Related]
4. Initial expression of interferon alpha receptor 2 (IFNAR2) on CD34-positive cells and its down-regulation correlate with clinical response to interferon therapy in chronic myelogenous leukemia.
Ito K; Tanaka H; Ito T; Sultana TA; Kyo T; Imanaka F; Ohmoto Y; Kimura A
Eur J Haematol; 2004 Sep; 73(3):191-205. PubMed ID: 15287917
[TBL] [Abstract][Full Text] [Related]
5. Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis.
Gilli F; Marnetto F; Caldano M; Sala A; Malucchi S; Di Sapio A; Capobianco M; Bertolotto A
J Neuroimmunol; 2005 Jan; 158(1-2):195-203. PubMed ID: 15589054
[TBL] [Abstract][Full Text] [Related]
6. IFNbeta bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays.
Capra R; Sottini A; Cordioli C; Serana F; Chiarini M; Caimi L; Padovani A; Bergamaschi R; Imberti L
J Neuroimmunol; 2007 Sep; 189(1-2):102-10. PubMed ID: 17619058
[TBL] [Abstract][Full Text] [Related]
7. Implication of the Toll-like receptor 4 pathway in the response to interferon-β in multiple sclerosis.
Bustamante MF; Fissolo N; Río J; Espejo C; Costa C; Mansilla MJ; Lizasoain I; Moro MA; Carmen Edo M; Montalban X; Comabella M
Ann Neurol; 2011 Oct; 70(4):634-45. PubMed ID: 22028223
[TBL] [Abstract][Full Text] [Related]
8. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
Hesse D; Sellebjerg F; Sorensen PS
Neurology; 2009 Aug; 73(5):372-7. PubMed ID: 19652141
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis.
Sriram U; Barcellos LF; Villoslada P; Rio J; Baranzini SE; Caillier S; Stillman A; Hauser SL; Montalban X; Oksenberg JR
Genes Immun; 2003 Mar; 4(2):147-52. PubMed ID: 12618863
[TBL] [Abstract][Full Text] [Related]
10. Modulation of IFNAR1 mRNA expression in multiple sclerosis patients.
Serana F; Sottini A; Ghidini C; Zanotti C; Capra R; Cordioli C; Caimi L; Imberti L
J Neuroimmunol; 2008 Jun; 197(1):54-62. PubMed ID: 18482773
[TBL] [Abstract][Full Text] [Related]
11. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort.
McKay F; Schibeci S; Heard R; Stewart G; Booth D
J Immunol Methods; 2006 Mar; 310(1-2):20-9. PubMed ID: 16448664
[TBL] [Abstract][Full Text] [Related]
12. MxA protein induction in MS patients treated with intramuscular IFNbeta-1a.
Vallittu AM; Salmi AA; Erälinna JP;
Neurol Sci; 2006 Feb; 26(6):438-43. PubMed ID: 16601938
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
Bertolotto A; Sala A; Caldano M; Capobianco M; Malucchi S; Marnetto F; Gilli F
J Immunol Methods; 2007 Apr; 321(1-2):19-31. PubMed ID: 17335844
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis.
Cepok S; Schreiber H; Hoffmann S; Zhou D; Neuhaus O; von Geldern G; Hochgesand S; Nessler S; Rothhammer V; Lang M; Hartung HP; Hemmer B
Arch Neurol; 2009 Oct; 66(10):1216-23. PubMed ID: 19667211
[TBL] [Abstract][Full Text] [Related]
15. T cell gene expression profiling identifies distinct subgroups of Japanese multiple sclerosis patients.
Satoh J; Nakanishi M; Koike F; Onoue H; Aranami T; Yamamoto T; Kawai M; Kikuchi S; Nomura K; Yokoyama K; Ota K; Saito T; Ohta M; Miyake S; Kanda T; Fukazawa T; Yamamura T
J Neuroimmunol; 2006 May; 174(1-2):108-18. PubMed ID: 16564577
[TBL] [Abstract][Full Text] [Related]
16. Expression of Th1 and Th17 cytokines and transcription factors in multiple sclerosis patients: does baseline T-bet mRNA predict the response to interferon-beta treatment?
Drulovic J; Savic E; Pekmezovic T; Mesaros S; Stojsavljevic N; Dujmovic-Basuroski I; Kostic J; Vasic V; Mostarica Stojkovic M; Popadic D
J Neuroimmunol; 2009 Oct; 215(1-2):90-5. PubMed ID: 19695714
[TBL] [Abstract][Full Text] [Related]
17. Anti-interferon-beta neutralising activity is not entirely mediated by antibodies.
Gilli F; Marnetto F; Caldano M; Valentino P; Granieri L; Di Sapio A; Capobianco M; Sala A; Malucchi S; Kappos L; Lindberg RL; Bertolotto A
J Neuroimmunol; 2007 Dec; 192(1-2):198-205. PubMed ID: 17950468
[TBL] [Abstract][Full Text] [Related]
18. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.
Pachner AR; Dail D; Pak E; Narayan K
J Neuroimmunol; 2005 Sep; 166(1-2):180-8. PubMed ID: 16005084
[TBL] [Abstract][Full Text] [Related]
19. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
Pachner AR; Cadavid D; Wolansky L; Skurnick J
Neurology; 2009 Nov; 73(18):1485-92. PubMed ID: 19884576
[TBL] [Abstract][Full Text] [Related]
20. High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study.
Millonig A; Rudzki D; Hölzl M; Ehling R; Gneiss C; Künz B; Berger T; Reindl M; Deisenhammer F
Mult Scler; 2009 Aug; 15(8):977-83. PubMed ID: 19465447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
